Lineage Cell Therapeutics (LCTX) Other Accumulated Expenses (2011 - 2023)

Lineage Cell Therapeutics has reported Other Accumulated Expenses for 13 years, with the latest figure at $1000.0 in Q2 2023.

• For the quarter ending Q2 2023, Other Accumulated Expenses fell 90.0% year-over-year to $1000.0; the trailing twelve-month figure through Jun 2023 stood at $1000.0 (down 90.0% YoY), and the FY2021 full-year result was $178000.0, up 1877.78% from the prior year.
• Other Accumulated Expenses for Q2 2023 stood at $1000.0, down from $37000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $492000.0 in Q2 2021, with the low at $1000.0 in Q2 2023.
• Historically, Other Accumulated Expenses has averaged $78187.5 across 5 years, with a median of $31000.0 in 2022.
• Annual changes were most pronounced in 2021 — Other Accumulated Expenses soared 1877.78% — and 2022, when it tumbled 97.97%.
• Lineage Cell Therapeutics' Other Accumulated Expenses stood at $4000.0 in 2019, then soared by 125.0% to $9000.0 in 2020, then soared by 1877.78% to $178000.0 in 2021, then tumbled by 85.96% to $25000.0 in 2022, then plunged by 96.0% to $1000.0 in 2023.
• The last three Other Accumulated Expenses figures came in at $1000.0 (Q2 2023), $37000.0 (Q1 2023), and $25000.0 (Q3 2022), per Business Quant data.